# Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia

> **NCT06603142** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd** · enrollment: 636 (estimated)

## Conditions studied

- Primary Gout
- Hyperuricemia

## Interventions

- **DRUG:** Febuxostat 20MG Tablets
- **DRUG:** Febuxostat 20MG Placebo
- **DRUG:** AR882 25MG
- **DRUG:** AR882 12.5MG
- **DRUG:** AR882 25MG Placebo
- **DRUG:** AR882 12.5MG Placebo
- **DRUG:** Febuxostat 40MG Tablets
- **DRUG:** Febuxostat 40MG Placebo

## Key facts

- **NCT ID:** NCT06603142
- **Lead sponsor:** Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-22
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 636 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06603142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06603142, "Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06603142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*